BACKGROUND: The relative role of IgA anomalies and genetic factors in IgA nephropathy (IgAN) recurrence after transplantation has never been investigated in a single cohort. METHODS: Sixty-one transplanted patients who had IgAN as an original disease (30 with biopsy-proved early recurrence, median 2.9 yr post-transplant), and 120 controls, were investigated for aberrantly glycosylated IgA1, IgA binding to mesangial matrix, macromolecular IgA (IgA/fibronectin and uteroglobulin/IgA/fibronectin complexes), and polymorphisms of cytokines [tumor necrosis factor alpha (TNFalpha), interleukin 10 (IL-10), IL-6, interferon gamma and transforming growth factor beta 1] and renin-angiotensin system (angiotensinogen converting enzyme, angiotensin II receptor 1, and angiotensinogen) genes. RESULTS: At multivariate logistic regression analysis, recurrence showed a border-line association with aberrantly glycosylated IgA1 [odds ratio (OR) 8.172, p = 0.077], and was significantly less frequent in carriers of -308 AG/AA TNF-alpha"high producer" genotype (OR 0.125, p = 0.036) and -1082, -819, -592 ACC/ATA IL-10 "low producer" (OR 0.038, p = 0.009) genotypes. CONCLUSION: High levels of aberrantly glycosylated IgA1 do not appear to play a strong crucial role in recurrence of IgAN. Polymorphisms of TNFalpha and IL-10 known to condition Th1 prevalence were associated with protection from early recurrence of IgAN.
BACKGROUND: The relative role of IgA anomalies and genetic factors in IgAnephropathy (IgAN) recurrence after transplantation has never been investigated in a single cohort. METHODS: Sixty-one transplanted patients who had IgAN as an original disease (30 with biopsy-proved early recurrence, median 2.9 yr post-transplant), and 120 controls, were investigated for aberrantly glycosylated IgA1, IgA binding to mesangial matrix, macromolecular IgA (IgA/fibronectin and uteroglobulin/IgA/fibronectin complexes), and polymorphisms of cytokines [tumor necrosis factor alpha (TNFalpha), interleukin 10 (IL-10), IL-6, interferon gamma and transforming growth factor beta 1] and renin-angiotensin system (angiotensinogen converting enzyme, angiotensin II receptor 1, and angiotensinogen) genes. RESULTS: At multivariate logistic regression analysis, recurrence showed a border-line association with aberrantly glycosylated IgA1 [odds ratio (OR) 8.172, p = 0.077], and was significantly less frequent in carriers of -308 AG/AA TNF-alpha"high producer" genotype (OR 0.125, p = 0.036) and -1082, -819, -592 ACC/ATA IL-10 "low producer" (OR 0.038, p = 0.009) genotypes. CONCLUSION: High levels of aberrantly glycosylated IgA1 do not appear to play a strong crucial role in recurrence of IgAN. Polymorphisms of TNFalpha and IL-10 known to condition Th1 prevalence were associated with protection from early recurrence of IgAN.
Authors: Laureline Berthelot; Thomas Robert; Vincent Vuiblet; Thierry Tabary; Antoine Braconnier; Moustapha Dramé; Olivier Toupance; Philippe Rieu; Renato C Monteiro; Fatouma Touré Journal: Kidney Int Date: 2015-06-10 Impact factor: 10.612
Authors: Roberta Camilla; Hitoshi Suzuki; Valentina Daprà; Elisa Loiacono; Licia Peruzzi; Alessandro Amore; Gian Marco Ghiggeri; Gianna Mazzucco; Francesco Scolari; Ali G Gharavi; Gerald B Appel; Stéphan Troyanov; Jan Novak; Bruce A Julian; Rosanna Coppo Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: R Coppo; R Camilla; A Amore; L Peruzzi; V Daprà; E Loiacono; S Vatrano; C Rollino; V Sepe; T Rampino; A Dal Canton Journal: Clin Exp Immunol Date: 2009-11-05 Impact factor: 4.330
Authors: Hyewon Park; Nuri Lee; Ji Won In; Eun Youn Roh; Kyoung Un Park; Sue Shin; Jaeseok Yang; Eun Young Song Journal: Ann Lab Med Date: 2017-09 Impact factor: 3.464
Authors: Min Jeong Kim; Stefan Schaub; Karen Molyneux; Michael T Koller; Susanne Stampf; Jonathan Barratt Journal: PLoS One Date: 2016-12-08 Impact factor: 3.240